Brainstorm Cell Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|
Revenue | $0 | $365 | $-569 |
Gross Profit | 301 | -633 | |
EBITDA | -2,989 | -2,477 | -2,410 |
EBIT | -3,048 | -2,541 | -2,474 |
Net Income | -2,708 | -2,541 | -3,401 |
Net Change In Cash | 0 | 365 | -569 |
Free Cash Flow | -3,299 | -1,683 | -3,063 |
Cash | 168 | 3,469 | 779 |
Basic Shares | 5,309 | 4,747 | 64,738 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -265 | -285 | -260 | -219 |
EBITDA | -16,927 | -24,537 | -24,279 | -31,465 |
EBIT | -17,192 | -24,822 | -24,539 | -31,684 |
Net Income | -17,192 | -23,732 | -24,375 | -31,938 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -18,973 | 37,293 | ||
Free Cash Flow | -20 | -19,349 | -26,595 | -35,571 |
Cash | 1,300 | 772 | 18,856 | 37,829 |
Basic Shares | 43,075 | 36,509 | 36,181 | 29,848 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.51 |
2024-06-30 | -$0.04 |
2024-03-31 | -$0.04 |
2023-12-31 | -$1.50 |
